LFWD.NASDAQLifeward LTD

DEF 14A: ReWalk Robotics Seeks Shareholder Approval for Name Change, Executive Compensation Adjustments

Sentiment:

Proxy Statement


ReWalk Robotics (Lifeward) is holding its 2024 Annual Meeting of Shareholders to vote on key proposals including a name change, director elections, executive compensation, and reappointment of its accounting firm.

Summary

  • ReWalk Robotics Ltd., doing business as Lifeward, is holding its 2024 Annual Meeting of Shareholders on September 4, 2024, to vote on several key proposals.
  • Shareholders will vote to re-elect two Class I directors, Hadar Levy and Joseph Turk, for terms expiring in 2027.
  • A key proposal involves changing the company's name to Lifeward Ltd., pending approval by the Israel Registrar of Companies.
  • The meeting will also address the approval of the company's 2024 Incentive Compensation Plan and the annual fees for the Chairperson of the Board.
  • Shareholders will vote on a grant of 28,571 restricted stock units to CEO Larry Jasinski and changes to his variable compensation terms.
  • The issuance of equity compensation to board member Randel E. Richner for consulting services will also be voted on.
  • The reappointment of Kost Forer Gabbay & Kasierer as the independent registered public accounting firm for the year ending December 31, 2024, is up for approval.
  • An advisory vote on the company's executive compensation (Say-on-Pay) is also included.
  • The meeting will include a report on the company's business for the year ended December 31, 2023, and a review of the 2023 financial statements.

Sentiment

Score: 7

Explanation: The document is primarily informational, outlining proposals for shareholder voting. While there are some concerns regarding executive compensation, the overall tone is neutral and focused on corporate governance.

Positives

  • The proposed changes to executive compensation aim to better align management's interests with those of shareholders.
  • The new 2024 Incentive Compensation Plan is designed to enhance flexibility in granting equity awards.
  • The proposed name change reflects the company's broader goals following the acquisition of AlterG and expansion of its portfolio.

Negatives

  • The document highlights shareholder concerns regarding the link between CEO compensation and company performance, prompting changes to the compensation structure.
  • The 2023 Say-on-Pay vote received low support (26.1%), indicating shareholder dissatisfaction with the executive compensation program.

Risks

  • The proposed name change is subject to approval by the Israel Registrar of Companies, which may not be guaranteed.
  • Shareholder approval is required for several key proposals, and failure to obtain such approval could impact the company's plans.
  • The company's reliance on equity compensation may be affected if the 2024 Incentive Compensation Plan is not approved.

Future Outlook

The company aims to continue offering a competitive equity compensation program to attract and retain talented employees for continued growth and success.

Management Comments

  • Jeff Dykan, Chairman of the Board, is retiring and will not stand for re-election.
  • The Board appointed Joseph Turk to serve as Chairman of the Board, effective immediately following the Meeting and assuming the re-election of Mr. Turk as a member of the Board pursuant to Proposal 1.b.

Industry Context

The document does not provide specific details on how this announcement relates to broader industry trends or competitors.

Management Changes

RolePrevious PersonNew PersonEffective DateReason
Chairman of the BoardJeff DykanJoseph TurkImmediately following the Meeting (assuming re-election of Mr. Turk)Retirement of Jeff Dykan
Chairman of the Audit CommitteeJeff DykanJoseph TurkImmediately following the Meeting (assuming re-election of Mr. Turk)Retirement of Jeff Dykan
Member and Chairman of the Nominating and Corporate Governance CommitteeJeff DykanRandel E. RichnerImmediately following the MeetingRetirement of Jeff Dykan
Member of the Nominating and Corporate Governance CommitteeJoseph TurkMichael SwinfordImmediately following the MeetingAppointment of Joseph Turk as Chairman of the Board

Corporate Governance

Change TypeDescriptionEffective DateImpact Assessment
Committee MandateThe mandate of the Nominating and Corporate Governance Committee will be expanded to include compliance issues.Immediately following the MeetingThe committee's name and charter will be changed to reflect the expanded mandate.

Related Party Transactions

  • The document details a consulting agreement with Randel E. Richner, a member of the Board, and the proposed issuance of equity compensation for additional consulting services.

Stakeholder Impact

  • Shareholders are directly impacted by the proposals being voted on, including director elections, the company's name change, and executive compensation.
  • Employees may be affected by changes to the incentive compensation plan and executive compensation structures.
  • The company's success in obtaining reimbursement approvals from CMS impacts its financial performance and ability to serve patients.

Next Steps

  • Shareholders are urged to vote on the proposals outlined in the proxy statement.
  • The company will announce preliminary voting results at the Annual Meeting.
  • Final voting results will be reported on the company's website and in a Current Report on Form 8-K.

Key Dates

DateDescription
2020-12-31Start date for historical stock performance period.
2024-07-24Record date for the Annual Meeting of Shareholders.
2024-07-29Date proxy materials are first being mailed to shareholders.
2024-08-28Deadline for shareholders to submit position statements.
2024-09-03Deadline for proxy card submission.
2024-09-04Date of the 2024 Annual Meeting of Shareholders.
2025Date of the 2025 Annual Meeting of Shareholders.
2025-04-02Deadline for shareholder proposals for the 2025 Annual Meeting.
2025-07-06Deadline for shareholders intending to solicit proxies in support of director nominees to provide notice.

Keywords

Shareholders, Compensation, Directors, Lifeward, ReWalk Robotics, Incentive Plan, Proxy Statement, Annual Meeting

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.